CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 652 enrolled
Drug / intervention
Role of Sacubitril/Valsartan in Hemodynamic and Echocardiographic Improvement of Heart Failure With Reduced Ejection Fractionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04397302
NCT04397302N/ACompleted
CompareCT.gov

Reverse Remodeling is Associated With Hemodynamic Improvement and Stabilization in Outpatients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan: an Echocardiographic Study

Italian Society of Cardiology·observational·Posted May 21, 2020·Updated May 28, 2020

In Brief

An observational study evaluating Role of Sacubitril/Valsartan in Hemodynamic and Echocardiographic Improvement of Heart Failure With Reduced Ejection Fraction for Heart Failure, Left Sided and 2 related conditions. Completed, enrolled 652 participants across 1 site.

Detailed Summary

This prospective study evaluates the mechanisms of benefit of sacubitril/valsartan in a population of outpatients with heart failure with reduced ejection fraction, to investigate the relationship between the effects on left ventricular ejection fraction and volumes and noninvasively hemodynamic echo-derived parameters, as cardiac output and left ventricular filling pressure.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure, Left Sided, Left Ventricular Dysfunction, Ventricular Remodeling
CountriesItaly
CollaboratorsUniversità degli Studi di Brescia, Federico II University, Ospedali Riuniti di Foggia, University Of Perugia, Monaldi Hospital, University of Messina, University of Siena, University of Salerno, Fondazione IRCCS Policlinico San Matteo di Pavia, Azienda Ospedaliero-Universitaria di Parma, Azienda Unita Sanitaria Locale di Piacenza

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedMay 21, 2020
Enrollment StartJan 13, 2019
Primary CompletionMar 16, 2020
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 6.1 years ago

Interventions

Role of Sacubitril/Valsartan in Hemodynamic and Echocardiographic Improvement of Heart Failure With Reduced Ejection Fractionother

Reverse Remodeling is Associated With Hemodynamic Improvement and Stabilization in Outpatients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan: an Echocardiographic Study